In recent years, everolimus and other mammalian target of rapamyoin (mTOR) inhibitors have been used in the treatment of TSC-related AML and achieved satisfactory results, which have been recommended as first-line treatment by guidelines [3]. The gene discussed is MTOR; the disease is tuberous sclerosis.